

Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis

James F. Donohue

UNC School of Medicine

Edward Kerwin

Clinical Research Institute of Southern Oregon, LLC

Chris N. Barnes

Theravance Biopharma

Edmund J. Moran

Theravance Biopharma

Brett Haumann

Theravance Biopharma

Glenn D. Crater (✉ GCrater@theravance.com)

Theravance Biopharma

Research article

Keywords: COPD, efficacy, long-acting muscarinic antagonist, nebulized therapy, revefenacin

Posted Date: April 26th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-15871/v4>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Version of Record: A version of this preprint was published at BMC Pulmonary Medicine on May 11th, 2020. See the published version at <https://doi.org/10.1186/s12890-020-1156-4>.

Abstract

Background: Revefenacin, a once-daily, long-acting muscarinic antagonist delivered via standard jet nebulizer, increased trough forced expiratory volume in 1 second (FEV1) in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) in prior phase 3 trials. We evaluated the efficacy of revefenacin in patients with markers of more severe COPD.

Methods: A post hoc subgroup analysis of two replicate, randomized, phase 3 trials was conducted over 12 weeks. Endpoints included least squares change from baseline in trough FEV1, St. George's Respiratory Questionnaire (SGRQ) responders, and transition dyspnea index (TDI) responders at Day 85. This analysis included patient subgroups at high risk for COPD exacerbations and compared patients who received revefenacin 175 µg and placebo: severe and very severe airflow limitation (percent predicted FEV1 30%–<50% and <30%), 2011 Global Initiative for Chronic Obstructive Lung Disease (GOLD) D, reversibility ($\geq 12\%$ and ≥ 200 mL increase in FEV1) to short-acting bronchodilators, concurrent use of long-acting β agonists and/or inhaled corticosteroids, older age (>65 and >75 years), and comorbidity risk factors.

Results: Revefenacin demonstrated significant improvements in FEV1 versus placebo at Day 85 among the intention-to-treat (ITT) population and all subgroups. Additionally, there was a greater number of SGRQ and TDI responders in the ITT population and the majority of subgroups analyzed among patients who received revefenacin versus placebo. For the SGRQ responders, the odds of response (odds ratio >2.0) were significantly greater in the revefenacin arm versus the placebo arm among the severe airflow obstruction, very severe airflow obstruction and 2011 GOLD D subgroups. For the TDI responders, the odds of response (odds ratio >2.0) were significantly greater among the severe airflow obstruction subgroup and patients aged >75 years.

Conclusions: Revefenacin showed significantly greater improvements in FEV1 versus placebo in the ITT population and all subgroups. Furthermore, there were a greater number of SGRQ and TDI responders in the ITT population, and in the majority of patient subgroups among patients who received revefenacin versus placebo. Based on the data presented, revefenacin could be a therapeutic option among patients with markers of more severe COPD.

Background

Inhaled drug delivery is the foundation of chronic obstructive pulmonary disease (COPD) pharmacological treatment [1]. The most common devices used to administer aerosolized medication in day-to-day respiratory practice are the pressurized metered-dose inhaler (MDIs) and dry powder inhaler (DPIs) [2]. The ability to use these inhalers adequately may become problematic among patients with COPD whose disease and symptoms become more severe. For pressurized MDIs, patients need to inhale correctly and coordinate breathing and actuation to ensure effective drug delivery. For DPIs, patients may struggle to generate sufficient inspiratory capacity to overcome the internal resistance of the device to de-aggregate the powdered drug into fine particles small enough for lung deposition [2, 3].

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) report recognize that markers (eg, symptoms and exacerbations), other than lung function impairment are associated with more severe disease [1]. Nebulized therapy may be an option in patients with more severe markers of COPD. Nebulized bronchodilators are recommended for patients with COPD who have very low inspiratory flow rates, physical, or mental impairments that preclude the use of inhalers, including elderly patients and patients with severe disease. They are also available to patients with COPD who prefer nebulized therapies [2, 4, 5].

Revefenacin inhalation solution is a once-daily long-acting muscarinic antagonist delivered by a standard jet nebulizer that was approved by the US Food and Drug Administration (FDA) for the maintenance treatment of patients with COPD [6]. The efficacy of revefenacin has been demonstrated in previous randomized, controlled, phase 3 trials in broad

populations of patients with moderate to very severe COPD with or without concurrent long-acting β agonist (LABA). Revefenacin significantly improved lung function (trough forced expiratory volume in 1 second [FEV₁] and overall treatment effect FEV₁) compared with placebo in two replicate 12-week studies [7]. Revefenacin treatment was shown to improve FEV₁ and respiratory health outcomes in a 52-week study with results similar to tiotropium via HandiHaler® [8]. Revefenacin was well tolerated for 52 weeks and has a safety profile that supports its long-term use in patients with COPD [9]. In addition, revefenacin was not associated with adverse cardiovascular events [10, 11]. Therefore, it may provide a beneficial treatment option for patients with cardiovascular disease, one of the most common comorbidities among patients with COPD [12].

Identifying patient subgroups who are most likely to benefit from nebulized long-acting muscarinic antagonist (LAMA) treatment can help clinicians direct therapy to patients at high risk for COPD exacerbations. Here, in this post hoc subgroup analysis, we evaluated the efficacy, and health outcomes of revefenacin 175 μ g versus placebo, in patients with markers of more severe COPD who participated in the replicate, placebo-controlled, 12-week phase 3 trials (0126 and 0127). Some of the methods and results of this analysis were previously reported in the form of an abstract [13].

Methods

Study design and conduct

Studies 0126 (NCT02459080) and 0127 (NCT02512510) were replicate, 12-week, randomized, double-blind, placebo-controlled, multiple-dose, parallel-group, phase 3 trials, and the design and conduct were described previously [7]. The studies were approved conducted according to the principles of the International Council on Harmonisation of Technical Requirements for Pharmaceuticals for Human Use guideline for good clinical practice [14], and the code of ethics of the World Medical Association's Declaration of Helsinki [15]; written informed consent was obtained from all patients. The protocol was reviewed and approved by an institutional review board (Quorum Review IRB, Seattle, Washington).

Patients

Inclusion and exclusion criteria have been described previously [7]. Briefly, patients aged ≥ 40 years with moderate to very severe COPD, a smoking history ≥ 10 pack-years, post-ipratropium FEV₁/forced vital capacity ratio < 0.7 , and post-ipratropium FEV₁ $< 80\%$ of predicted normal and > 700 mL at screening were enrolled. Concomitant LABAs (with or without inhaled corticosteroids [ICS]) was permitted in up to 40% of the study population to ensure robust assessments of concurrent therapies used by patients. Once the 40% cap was reached, new patients who entered screening required a 14-day washout of any LABA-containing therapy before the ipratropium reversibility test at screening. Patients taking ICS/LABA at enrollment were switched to receive ICS monotherapy at an equivalent dose for at least 14 days, before the ipratropium reversibility visit at screening. Stable doses of ICS without concomitant LABAs were permitted, but LAMAs and short-acting muscarinic antagonists were prohibited.

Patients were randomized (1:1:1) in a double-blind manner to receive revefenacin 175 μ g, revefenacin 88 μ g, or placebo once daily via PARI LC® Sprint (Starnberg, Germany) jet nebulizer for 12 weeks. Results with revefenacin 175 mg, which is the FDA-approved dose, are reported here.

Analysis population and endpoints

Endpoints of this study included the least squares (LS) change from baseline in trough FEV₁ at Day 85, St. George's Respiratory Questionnaire (SGRQ) responders, and transition dyspnea index (TDI) responders at Day 85. This analysis included the intention-to-treat (ITT) population and subgroups of patients at high risk for COPD exacerbations, and compared patients who received revefenacin 175 µg and placebo. The following subgroups of patients were analyzed: severe airflow limitation (percent predicted FEV₁ 30%–<50%), very severe airflow limitation (percent predicted FEV₁ <30%), 2011 GOLD D, patients that are reversible (≥12% and ≥200 mL increase in FEV₁) to short-acting bronchodilators (ipratropium and albuterol), background ICS, background LABA and/or ICS, older age (defined as 65 or >75 years), and comorbidity risk factors which included history of cardiovascular disease, diabetes mellitus, and cognitive/mental impairments.

Statistical analyses

The full analysis set included all randomized patients who received at least one dose of study drug and had at least one recorded post-baseline FEV₁ assessment. Pooled analyses were conducted using a repeated statement of subject ID nested within study instead of a random statement to ensure convergence. Changes from baseline in FEV₁ were analyzed using a mixed model for repeated measures. Trough FEV₁ at Day 85 is defined as the mean of the 23.25- and 23.75-hour spirometry assessments post the Day 84 dose. Trough FEV₁ at Days 15, 29, 57, and 84 is defined as the mean of the -45 min and -15 min pre-dose spirometry assessments. SGRQ and TDI responders were the proportions of patients with a reduction in SGRQ total score ≥4 units, or an increase in TDI score ≥1 unit (ie, minimum clinically important differences [MCID]), respectively [16, 17].

Results

Patient demographics and baseline characteristics

Data from 812 patients were pooled for analysis, with 395 patients receiving revefenacin 175 µg, and 417 patients receiving placebo (**Table 1**). Across both treatment groups, approximately 45% of patients were >65 years, 10% were >75 years, and 37% were on background LABA and/or ICS. In addition, approximately 31% of patients had severe airflow limitation (percent predicted FEV₁ 30%–<50%), and 34% met 2011 GOLD D criteria. For comorbidities, approximately 47%, 20%, and 15% of patients had a history of cardiovascular disease, diabetes mellitus, and cognitive/mental impairments, respectively. Overall, patient demographics and baseline characteristics from the pooled analysis indicated that revefenacin and placebo groups were well balanced across all variables (**Table 1**).

Changes from baseline in trough FEV₁

Across the ITT population and subgroups, revefenacin 175 µg produced significantly greater improvements in Day 85 trough FEV₁ than placebo (**Figure 1 and Table 2**). Of note, revefenacin demonstrated significantly greater improvements in trough FEV₁ among patients who are reversible to short-acting bronchodilators versus placebo (LS mean [95% confidence intervals] difference, 286.52 [214.8, 358.2] mL, $p<0.0001$), In addition, revefenacin demonstrated significant increases in FEV₁ among elderly patients (aged >75 years, and >65 years), providing additional 129–140 mL improvements versus placebo (both p -values <0.03). Among patients with comorbidities, revefenacin demonstrated significantly greater improvements in trough FEV₁ among patients with a history of diabetes mellitus, cardiovascular

disease, and cognitive/mental impairments, providing additional 102–150 mL improvements versus placebo (all p -values <0.03) (**Figure 1 and Table 2**).

SGRQ responders

In the ITT population, a higher proportion of patients in the revefenacin 175 µg arm (46.9%) met the MCID criteria of SGRQ responder than placebo (36.2%) (**Figure 2 and Table 3**), with the odds of response significantly greater in the revefenacin 175 µg arm than in the placebo arm ($p = 0.0116$). In general, the majority of subgroup analyses showed a higher rate of responders for revefenacin than for placebo, with the odds of response (odds ratio >2.0) significantly greater in the revefenacin arm than in the placebo arm, among the severe ($p = 0.037$) and very severe ($p < 0.001$) airflow limitations, and 2011 GOLD D ($p = 0.004$) subgroups. In addition, the cardiovascular disease subgroup showed a non-significant trend, with the odds of response exceeding 2.0; odds ratio 2.3 (95% confidence intervals 0.68–7.83, $p = 0.1822$) (**Figure 2 and Table 3**).

TDI responders

In the ITT population, a higher proportion of patients in the revefenacin arm (55.0%) met the MCID criteria of TDI responder than placebo (47.2%), with the odds of response greater in the revefenacin arm than in the placebo arm (**Figure 3 and Table 4**). Overall, the majority of subgroup analyses showed a higher rate of responders for revefenacin than for placebo, with the odds of response significantly greater among the severe airflow obstruction subgroup, odds ratio 2.37 (95% confidence intervals 1.10–5.08, $p = 0.027$), and a tendency towards significance in the 2011 GOLD D subgroup, odds ratio 1.95 (95% confidence intervals 0.93–4.09, $p = 0.079$). In addition, the odds of being a TDI responder were significantly greater in the revefenacin arm than in the placebo among patients aged >75 years; odds ratio 4.7 (95% confidence intervals 1.02–21.86, $p = 0.047$) (**Figure 3 and Table 4**).

Discussion

This post hoc subgroup analysis of two replicate, randomized, double-blind, placebo-controlled, parallel-group, 12-week phase 3 trials (0126 and 0127) provides evidence for the efficacy of revefenacin delivered by a standard jet nebulizer in patients with COPD that had markers of severe disease. This analysis of pooled data from Studies 0126 and 0127 in all subgroups of patients with COPD that had markers of severe disease, showed that revefenacin was associated with significant improvements in lung function (range, 102–176 mL), which was comparable with the ITT population (148 mL).

In addition, revefenacin demonstrated improvements in health-related quality of life (as measured by SGRQ responders) and dyspnea (as measured by TDI responders) in the majority of patient subgroups versus placebo; these improvements were also comparable to those observed in the ITT population. The odds of being a SGRQ responder were significantly greater among patients with severe airflow obstruction (percent predicted FEV₁ 30%– $<50\%$), very severe airflow obstruction (percent predicted FEV₁ $<30\%$), and those classified as 2011 GOLD D. Among patients with comorbidities, the odds of response in the revefenacin group with a history of cardiovascular disease showed a non-significant trend (odds ratio >2.0) compared with placebo. It is likely significance was not met due to the relatively small patient numbers. The odds of being a TDI responder were significantly greater among patients with severe airflow obstruction (percent

predicted FEV₁ 30%–<50%), and those aged >75 years, and there was a tendency towards significance in the 2011 GOLD D subgroup.

Results of this analysis are consistent with other studies that evaluated the efficacy of patients taking revefenacin and a concomitant LABA or LABA/ICS, or combining other LAMAs with LABA or LABA/ICS. Revefenacin 175 µg demonstrated improvements in FEV₁ in concomitant LABA patients in a 52 week study [8]. The efficacy of combined LAMA/LABA treatments has been shown to improve lung function and health outcomes [18–20]. In a systematic review and meta-analysis, it was reported that combining LAMA with LABA and ICS in patients with advanced COPD have better lung function and health-related quality of life and lower rates of moderate/severe COPD exacerbations than dual therapy or monotherapy [21].

In this analysis, revefenacin resulted in significant improvements in lung function, SGRQ and TDI among patients with severe airflow obstruction (percent predicted FEV₁ 30–<50%) and classified as GOLD D in this study, which is consistent with previous studies. Nebulized glycopyrrolate was shown to improve FEV₁, SGRQ, and TDI in patients with moderate to very severe COPD [22]. Furthermore, tiotropium demonstrated higher efficacy versus salmeterol in prolonging time to first COPD exacerbation and reducing number of exacerbations in patients both at high exacerbation risk [18]. In addition, aclidinium 400 µg significantly improved respiratory symptoms among patients who were classified as GOLD D at baseline [23].

Patients with COPD frequently have comorbid conditions, which can influence mortality and hospitalizations [1]. In this study, revefenacin demonstrated significant improvements in FEV₁ and health outcomes among patient subgroups with cardiovascular disease, and diabetes mellitus compared with patients who received placebo. Similarly, nebulized glycopyrrolate improved FEV₁, and patient-reported outcomes in patients with COPD, irrespective of cardiovascular risk status [24]. In previous studies of patients with COPD and comorbid type 2 diabetes, ICS therapy may have a negative impact on diabetes control, and patients prescribed higher doses may be at greater risk of diabetes progression [25, 26]. In the GOLD report, combination ICS/LABA or LAMA/LABA or LAMA monotherapy are recommended for GOLD D patients [1]. However, in patients with comorbid diabetes, it may be more appropriate to limit the use of ICS to the minority of patients with COPD who might benefit.

There were no safety issues identified with the use of revefenacin in patients with cardiac risk factors [7, 9]. In a preclinical study, revefenacin was shown to be a high-affinity competitive antagonist at human recombinant muscarinic acetylcholine receptors with kinetic functional selectivity for M₃ over M₂ muscarinic acetylcholine receptors [27]. In addition, revefenacin is a metabolically labile primary amide “soft-drug” site that allows rapid systemic clearance of the parent drug, thus potentially minimizing systemically mediated adverse events [27, 28].

Results of this analysis also demonstrated significant improvements in FEV₁ in patients who received revefenacin among subgroups aged >65 years and >75 years, and cognitive/mental impairments, versus those who received placebo. Similarly, a retrospective analysis demonstrated the efficacy and safety of tiotropium among elderly patients with COPD (<70 years, 70–79 years, and ≥80 years) [29]. Previous studies have suggested that nebulized therapy may be an appropriate option in patients with COPD and arthritis, impaired manual dexterity, chronic muscle weakness, or mental health or confusion disorders, or who are in hospitals, tertiary care centers, and assisted care settings as they may prefer nebulized therapy that is easy to use and does not require special training [2, 30].

Several limitations should be noted for this study. The treatment period was only three months, which does not allow for conclusions on long-term treatment. Due to small sample sizes in the subgroups and post hoc nature of this study, results should be interpreted with caution. The populations assessed in this study had stable COPD and did not include patients that had recent hospitalizations or respiratory infections. Peak inspiratory flow rate was not assessed at

baseline, and therefore, patients with a suboptimal peak inspiratory flow rate could not be assessed as a potential population with markers of more severe COPD.

Conclusions

In summary, in this post hoc subgroup analysis of data from Studies 0126 and 0127 among patients with markers of more severe COPD, revefenacin treatment showed significant improvements in lung function. In addition, there was a greater number of SGRQ and TDI responders in the ITT population and the majority of patient subgroups among patients who received revefenacin versus placebo. Based on the data presented, revefenacin could be a therapeutic option among patients with markers of more severe COPD.

Declarations

Abbreviations

COPD: Chronic obstructive pulmonary disease; DPI: Dry powder inhaler; FDA: Food and Drug Administration; FEV₁: Forced expiratory volume in 1 second; GOLD: Global Initiative for Chronic Obstructive Lung Disease; ICS: Inhaled corticosteroid; ITT: Intention-to-treat; LABA: Long-acting β agonist; LAMA: Long-acting muscarinic antagonist; MDI: Metered-dose inhaler; SGRQ: St. George's Respiratory Questionnaire; TDI: Transition dyspnea index.

Ethics approval and consent to participate

This study was conducted in accordance with the protocol, the principles of the International Council on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Guideline for Good Clinical Practice, the United States Code of Federal Regulations, the principles of the World Medical Association Declaration of Helsinki, Ethical Principles for Medical Research Involving Human Subjects, and all applicable regulatory requirements. The protocol was reviewed and approved by an institutional review board (Quorum Review IRB, Seattle, Washington). Written informed consent was obtained from all patients.

Consent for publication

Not applicable.

Availability of data and materials

Theravance Biopharma (and its affiliates) will not be sharing individual de-identified participant data or other relevant study documents. Theravance Biopharma reviews the appropriateness of public disclosure of de-identified study data on a regular basis; however, at this time, has determined that public disclosure is not appropriate for advancing the knowledge around COPD treatment.

Competing interests

JFD is a consultant and advisory committee member for Mylan Inc. and Sunovion Pharmaceuticals.

EK has participated in consulting, advisory boards, speaker panels, or received travel reimbursement for Amphastar, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Mylan, Novartis, Oriel, Pearl, Sunovion, Teva and Theravance Biopharma US, Inc. He has conducted multicenter clinical research trials for approximately 40 pharmaceutical companies.

CNB was an employee of Theravance Biopharma US, Inc. at the time this study was conducted.

EJM, BH, and GDC are current employees of Theravance Biopharma US, Inc.

Funding

This study was funded by Theravance Biopharma Ireland Limited (Dublin, Ireland). Mylan, Inc. (Canonsburg, Pennsylvania) and Theravance Biopharma US, Inc. (South San Francisco, California) funded medical writing support.

Theravance Biopharma Ireland Limited (Dublin, Ireland) contributed to the design of the study, data collection, analysis, and interpretation of data.

Theravance Biopharma US, Inc. (South San Francisco, California) contributed to the analysis and interpretation of data. Theravance Biopharma US, Inc. (South San Francisco, California) employees/authors contributed to the writing of the manuscript.

Mylan, Inc. (Canonsburg, Pennsylvania) contributed to the design of the study and interpretation of data.

Authors' contributions

JFD, EK, CNB, EJM, BH, and GDC take responsibility for the conception and design.

JFD, EK, CNB, EJM, BH, and GDC take responsibility for data analysis and interpretation.

JFD, EK, CNB, EJM, BH, and GDC take responsibility for drafting the manuscript for important intellectual content.

All authors approve the submitted version of the manuscript and agree to be accountable for the accuracy and integrity of the work.

Acknowledgments

The authors acknowledge Gráinne Faherty, MPharm, for medical writing and Frederique H. Evans, MBS, for editorial assistance in the preparation of the manuscript (Ashfield Healthcare Communications, Middletown, CT, USA).

References

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2019 report). <https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-POCKET-GUIDE-DRAFT-v1.7-14Nov2018-WMS.pdf>. Accessed 10 November 2019.
2. Tashkin D. A review of nebulized drug delivery in COPD. *Int J Chron Obstruct Pulmon Dis*. 2016;11:2585–96.

3. Muralidharan P, Hayes Jr D, Mansour H. Dry powder inhalers in COPD, lung inflammation and pulmonary infections. *Expert Opin Drug Deliv.* 2015;12:947–62.
4. Dhand R, Dolovich M, Chipps B, Myers T, Restrepo R, Farrar J. The role of nebulized therapy in the management of COPD: evidence and recommendations. *COPD.* 2012;9:58–72.
5. Jarvis S, Ind P, Shiner R. Inhaled therapy in elderly COPD patients; time for re-evaluation? *Age Ageing.* 2007;36:213–218.
6. US Food and Drug Administration. HIGHLIGHTS OF PRESCRIBING INFORMATION YUPELRI® (revefenacin) inhalation solution, for oral inhalation. 2018.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210598s000lbl.pdf. Accessed 10 November 2019.
7. Ferguson G, Feldman G, Pudi K, Barnes C, Moran E, Haumann B, et al. Improvements in lung function with nebulized revefenacin in the treatment of patients with moderate to very severe COPD: results from two replicate phase III clinical trials *Chronic Obstr Pulm Dis.* 2019;6:154–65.
8. Donohue J, Kerwin E, Sethi S, Haumann B, Pendyala S, Dean L, et al. Maintained therapeutic effect of revefenacin over 52 weeks in moderate to very severe chronic obstructive pulmonary disease (COPD). *Respir Res* 2019;20(1):241.
9. Donohue J, Kerwin E, Sethi S, Haumann B, Pendyala S, Dean L, et al. Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized Therapy: safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary disease. *Respir Med* 2019;153:38–43.
10. Borin M, Barnes C, Darpo B, Pendyala S, Xue H, Bourdet D. Revefenacin, a long-acting muscarinic antagonist, does not prolong QT interval in healthy subjects: results of a placebo- and positive-controlled thorough QT study. *Clin Pharmacol Drug Dev.* <https://accp1.onlinelibrary.wiley.com/doi/full/10.1002/cpdd.732>. Accessed 10 November 2019.
11. Donohue J, Feldman G, Sethi S, Barnes C, Pendyala S, Bourdet D, et al. Cardiovascular safety of revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy of chronic obstructive pulmonary disease. *Pulm Pharmacol Ther.* 2019;101808.
12. Mannino D, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. *Eur Respir J.* 2008;32:962–9.
13. Donohue J, Kerwin E, Barnes C, Moran E, Haumann B, Pendyala S, et al. Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy in chronic obstructive pulmonary disease patients with markers of more severe disease. *Chest.* 2018;154:736A–737A.
14. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Integrated addendum to ICH E6(r1): guideline for good clinical practice E6 (R2). 2015.
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R2__Addendum_Step2.pdf. Accessed 10 November 2019.
15. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. *JAMA.* 2013;310:2191–4.
16. Jones P. St. George's respiratory questionnaire: MCID. *COPD.* 2005;2:75–9.
17. Mahler D, Witek T. The MCID of the transition dyspnea index is a total score of one unit. *COPD.* 2005;2:99–103.
18. Vogelmeier C, Asijee G, Kupas K, Beeh K. Tiotropium and salmeterol in COPD Patients at risk of exacerbations: A post hoc analysis from POET-COPD®. *Adv Ther.* 2015;32:537–47.
19. Vogelmeier C, Paggiaro P, Dorca J, Sliwinski P, Mallet M, Kirsten A, et al. Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study. *Eur Respir J.* 2016;48:1030–9.
20. Wedzicha J, Banerji D, Chapman K, Vestbo J, Roche N, Ayers R, et al. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. *N Engl J Med.* 2016;374:2222–34.

21. Zheng Y, Zhu J, Liu Y, Lai W, Lin C, Qiu K, et al. Triple therapy in the management of chronic obstructive pulmonary disease: systematic review and meta-analysis. *BMJ*. 2018;363:k4388.
22. Kerwin E, Donohue J, Goodin T, Tosiello R, Wheeler A, Ferguson G. Efficacy and safety of glycopyrrolate/eFlow[®] CS (nebulized glycopyrrolate) in moderate-to-very-severe COPD: Results from the glycopyrrolate for obstructive lung disease via electronic nebulizer (GOLDEN) 3 and 4 randomized controlled trials. *Respir Med*. 2017;132:238–50.
23. Wedzicha J, Agusti A, Donaldson G, Chuecos F, Lamarca R, Garcia Gil E. Effect of aclidinium bromide on exacerbations in patients with moderate-to-severe COPD: a pooled analysis of five phase III, randomized, placebo-controlled studies. *COPD*. 2016;13:669–76.
24. Ferguson G, Tosiello R, Sanjar S, Goodin T. Efficacy and safety of nebulized glycopyrrolate/eFlow[®] closed system in patients with moderate-to-very-severe chronic obstructive pulmonary disease with pre-existing cardiovascular risk factors. *Chronic Obstr Pulm Dis*. 2018;6:86–99.
25. Herth F, Bramlage P, Müller-Wieland D. Current perspectives on the contribution of inhaled corticosteroids to an increased risk for diabetes onset and progression in patients with chronic obstructive pulmonary disease. *Respiration*. 2015;89:66–75.
26. Price D, Russell R, Mares R, Burden A, Skinner D, Mikkelsen H, et al. Metabolic effects associated with ICS in patients with COPD and comorbid Type 2 Diabetes: a historical matched cohort study. *PLoS One*. 2016;11:e0162903.
27. Quinn D, Barnes C, Yates W, Bourdet D, Moran E, Potgieter P, et al. Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies. *Pulm Pharmacol Ther*. 2018;48:71–9.
28. Ji Y, Husfeld C, Pulido-Rios M, Mcnamara A, Obedencio G, Baldwin M, et al. Duration by design: discovery of revefenacin, the first-in-class nebulized once-daily bronchodilator for the treatment of patients with COPD. *Chest*. 2016;150.
29. Satoh H, Kagohashi K, Ohara G, Sato S, Miyazaki K, Nakazawa K, et al. Use of tiotropium in patients with COPD aged 80 years and older. *Exp Ther Med*. 2013;5:997–1000.
30. Dolovich M, Ahrens R, Hess D, Anderson P, Dhand R, Rau J, et al. Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. *Chest*. 2005;127:335–71.

Tables

Table 1. Pooled population demographics and baseline characteristics

Characteristic	Revefenacin 175 µg (n = 395)	Placebo (n = 417)
Sex, male, n (%)	195 (49.4)	206 (49.4)
>65 years, n (%)	176 (44.6)	185 (44.4)
>75 years, n (%)	35 (8.9)	42 (10.1)
Current smoker, n (%)	190 (48.1)	198 (47.5)
Concurrent LABA or ICS/LABA, n (%)	153 (38.7)	147 (35.3)
Concurrent ICS, n (%)	174 (44.1)	171 (41.0)
FEV ₁ 30%–<50% pred, n (%)	119 (30.1)	134 (32.1)
FEV ₁ <30% pred, n (%)	26 (6.6)	16 (3.8)
2011 GOLD category D, n (%)	132 (33.4)	141 (33.8)
Reversible to ipratropium and albuterol, n (%)	86 (21.8)	82 (19.7)
History of cardiovascular disease ^a	178 (45.1)	200 (48.0)
History of diabetes	80 (20.3)	78 (18.7)
History of cognitive/mental impairments	58 (14.7)	61 (14.6)

^aCardiovascular risk factors: aged ≥60 years and any two of the following conditions: diabetes, hypercholesterolemia, hypertension, peripheral vascular disorder or cardiac disorders from reported medical history or aged ≥40 years and a cardiac disorder(s) from reported medical history.

FEV₁ = forced expiratory volume in 1 second; GOLD = Global Initiative for Chronic Obstructive Lung Disease; ICS = inhaled corticosteroids; LABA = long-acting β agonist.

Table 2. Day 85 trough FEV₁ (mL) by patient subgroup

Subgroups	Revefenacin 175 µg (n = 395)	Placebo (n = 417)
ITT		
Evaluable n	310	296
LS mean difference (95% CI)	148.1 (115.2,181.1); <i>p</i> <0.0001	
FEV₁ 30%–<50% pred		
Evaluable n	101	78
LS mean difference (95% CI)	131.2 (70.7, 191.6), <i>p</i> <0.0001	
FEV₁ <30% pred		
Evaluable n	17	9
LS mean difference (95% CI)	176.2 (14.7, 337.5), <i>p</i> = 0.0324	
2011 GOLD category D		
Evaluable n	108	83
LS mean difference (95% CI)	124.6 (66.5, 182.7), <i>p</i> <0.0001	
ICS use		
Evaluable n	135	108
LS mean difference (95% CI)	130.6 (78.7, 182.5), <i>p</i> <0.001	
LABA or ICS/LABA use		
Evaluable n	118	89
LS mean difference (95% CI)	139.2 (82.9, 195.5), <i>p</i> <0.0001	
>65 years		
Evaluable n	143	128
LS mean difference (95% CI)	140.3 (91.0, 189.7), <i>p</i> <0.0001	
>75 years		
Evaluable n	28	25
LS mean difference (95% CI)	129.2 (18.9, 239.5), <i>p</i> = 0.0217	

Reversible to ipratropium and albuterol		
Evaluable n	70	57
LS mean difference (95% CI)	286.5 (214.8, 358.2), $p < 0.0001$	
History of CV disease		
Evaluable N	21	27
LS mean difference (95% CI)	140.7 (18.4, 263.0), $p = 0.0242$	
History of diabetes		
Evaluable N	85	57
LS mean difference (95% CI)	101.6 (27.0, 176.3), $p = 0.0077$	
History of cognitive/mental impairments		
Evaluable N	45	44
LS mean difference (95% CI)	149.5 (64.5, 234.5), $p = 0.0006$	

CI = confidence intervals; CV = cardiovascular; FEV₁ = forced expiratory volume in 1 second; GOLD = Global Initiative for Chronic Obstructive Lung Disease, LABA = long-acting β agonist; ICS = inhaled corticosteroids; ITT = intention-to-treat; pred = predicted.

Table 3. Day 85 SGRQ responders by patient subgroup

Subgroups	Revefenacin 175 µg (n = 395)	Placebo (n = 417)
ITT		
Evaluable n	288	276
Odds ratio (95% CI)	1.53 (1.10, 2.13), <i>p</i> = 0.0116	
FEV₁ 30%–<50% pred		
Evaluable n	96	78
Odds ratio (95% CI)	1.99 (1.04, 3.81), <i>p</i> = 0.0368	
FEV₁ <30% pred		
Evaluable n	16	7
Odds ratio (95% CI)	2×10^{10} ($3.05 \times 10^7, 126 \times 10^9$), <i>p</i> < 0.001	
2011 GOLD category D		
Evaluable n	103	81
Odds ratio (95% CI)	2.52 (1.34, 4.76), <i>p</i> = 0.0042	
ICS use		
Evaluable n	134	105
Odds ratio (95% CI)	1.23 (0.74, 2.03), <i>p</i> = 0.4291	
LABA or ICS/LABA use		
Evaluable n	118	85
Odds ratio (95% CI)	1.34 (0.77, 2.35), <i>p</i> = 0.2995	
>65 years		
Evaluable n	133	119
Odds ratio (95% CI)	1.11 (0.67, 1.84), <i>p</i> = 0.6897	
>75 years		
Evaluable n	28	25
Odds ratio (95% CI)	0.58 (0.19, 1.81), <i>p</i> = 0.3506	

Reversible to ipratropium and albuterol		
Evaluable n	66	51
Odds ratio (95% CI)	1.12 (0.55, 2.30), <i>p</i> = 0.7486	
History of CV disease		
Evaluable N	19	25
Odds ratio (95% CI)	2.30 (0.68, 7.83), <i>p</i> = 0.1822	
History of diabetes		
Evaluable N	60	53
Odds ratio (95% CI)	1.31 (0.63, 2.75), <i>p</i> = 0.4704	
History of cognitive/mental impairments		
Evaluable N	43	40
Odds ratio (95% CI)	1.18 (0.49, 2.88), <i>p</i> = 0.7126	

CI = confidence intervals; CV = cardiovascular; FEV₁ = forced expiratory volume in 1 second; GOLD = Global Initiative for Chronic Obstructive Lung Disease, LABA = long-acting β agonist; ICS = inhaled corticosteroids; ITT = intention-to-treat; pred = predicted.

Table 4. Day 85 TDI responders by patient subgroup

Subgroups	Revefenacin 175 µg (n = 395)	Placebo (n = 417)
ITT		
Evaluable n	280	271
Odds ratio (95% CI)	1.46 (0.96, 2.22), <i>p</i> = 0.0760	
FEV₁ 30%–<50% pred		
Evaluable n	95	77
Odds ratio (95% CI)	2.37 (1.10, 5.08), <i>p</i> = 0.0268	
FEV₁ <30% pred		
Evaluable n	15	7
Odds ratio (95% CI)	0.31 (0.03, 2.88), <i>p</i> = 0.3016	
2011 GOLD category D		
Evaluable n	101	80
Odds ratio (95% CI)	1.95 (0.93, 4.09), <i>p</i> = 0.0789	
ICS use		
Evaluable n	131	100
Odds ratio (95% CI)	1.04 (0.54, 1.98), <i>p</i> = 0.9115	
LABA or ICS/LABA use		
Evaluable n	116	81
Odds ratio (95% CI)	1.16 (0.57, 2.35), <i>p</i> = 0.6845	
>65 years		
Evaluable n	131	115
Odds ratio (95% CI)	1.43 (0.76, 2.68), <i>p</i> = 0.2687	
>75 years		
Evaluable n	28	25
Odds ratio (95% CI)	4.72 (1.02, 21.86), <i>p</i> = 0.0470	

Reversible to ipratropium and albuterol		
Evaluable n	63	50
Odds ratio (95% CI)	1.72 (0.67, 4.38), <i>p</i> = 0.2583	
History of CV disease		
Evaluable N	18	25
Odds ratio (95% CI)	1.62 (0.93, 2.22), <i>p</i> = 0.5397	
History of diabetes		
Evaluable N	61	51
Odds ratio (95% CI)	1.41 (0.55, 3.64), <i>p</i> = 0.4719	
History of cognitive/mental impairments		
Evaluable N	41	38
Odds ratio (95% CI)	1.03 (0.34, 3.10), <i>p</i> = 0.9552	

CI = confidence intervals; CV = cardiovascular; FEV₁ = forced expiratory volume in 1 second; GOLD = Global Initiative for Chronic Obstructive Lung Disease, LABA = long-acting β agonist; ICS = inhaled corticosteroids; ITT = intention-to-treat; pred = predicted.

Figures




Figure 1

Day 85 trough FEV1 by patient subgroup The LS mean difference for revafenacin versus placebo was statistically significant ($p < 0.05$) for all subgroups. CI = confidence intervals; CV = cardiovascular; FEV1 = forced expiratory volume in 1 second; GOLD = Global Initiative for Chronic Obstructive Lung Disease; LABA = long-acting β agonist; ICS = inhaled corticosteroids; ITT = intention-to-treat.




Figure 2

Day 85 SGRQ responders by patient subgroup The odds ratios for revafenacin versus placebo was statistically significant ($p < 0.05$) for the following subgroups: ITT, FEV₁ 30%–<50% predicted and, 2011 GOLD category D. The subgroup, FEV₁ <30% predicted, has been excluded from the forest plot due to being out with the range of the x-axis scale. CI = confidence intervals; CV = cardiovascular; FEV₁ = forced expiratory volume in 1 second; GOLD = Global Initiative for Chronic Obstructive Lung Disease; LABA = long-acting β agonist; ICS = inhaled corticosteroids; ITT = intention-to-treat; SGRQ, St. George’s Respiratory Questionnaire.




Figure 3

Day 85 TDI responders by patient subgroup The odds ratios for revafenacin versus placebo was statistically significant ($p < 0.05$) for the following subgroups: FEV₁ 30%–<50% predicted, and >75 years. CI = confidence intervals; CV = cardiovascular; FEV₁ = forced expiratory volume in 1 second; GOLD = Global Initiative for Chronic Obstructive Lung Disease; LABA = long-acting β agonist; ICS = inhaled corticosteroids; ITT = intention-to-treat; TDI = transition dyspnea index.